Kamada Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KMDA Nasdaq 2836 https://www.kamada.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kamada Ltd.

KMDA: 2022 Revenue of $129 Million; Expected 2023 Revenues of $138 Million to $146 Million and Continued Positive Operating Cash Flow… - Mar 20th, 2023 2:36 pm
Kamada Ltd. (NASDAQ:KMDA) Q4 2022 Earnings Call Transcript - Mar 18th, 2023 6:55 am
Kamada Issues 2023 CEO Letter to Shareholders - Mar 15th, 2023 11:10 am
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth - Mar 15th, 2023 11:00 am
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023 - Mar 9th, 2023 1:00 pm
KMDA: Initiating Coverage on Kamada Ltd; A Commercial Stage Biopharmaceutical Company with a Portfolio of Marketed Products… - Feb 13th, 2023 11:05 am
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel - Jan 4th, 2023 12:00 pm
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day - Dec 28th, 2022 11:51 am
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Dec 27th, 2022 2:05 pm
Kamada Ltd. (NASDAQ:KMDA) Q3 2022 Earnings Call Transcript - Dec 25th, 2022 5:11 pm
Kamada Announces Planned Transition of Chief Financial Officer - Dec 19th, 2022 12:00 pm
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK - Dec 15th, 2022 2:07 pm
Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data - Dec 2nd, 2022 3:54 pm
New Strong Buy Stocks for November 28th - Nov 28th, 2022 12:39 pm
AcuCort signs its first commercial agreement for the company's drug Zeqmelit™ - Nov 23rd, 2022 4:42 pm
Kamada (KMDA) Q3 Earnings and Revenues Top Estimates - Nov 22nd, 2022 1:25 pm
Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance - Nov 22nd, 2022 12:00 pm
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022 - Nov 16th, 2022 12:00 pm
Science 37 Holdings, Inc. (SNCE) Reports Q3 Loss, Misses Revenue Estimates - Nov 10th, 2022 10:25 pm
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT - Nov 7th, 2022 12:00 pm